Antidepressant Drug Effects and Depression Severity A Patient-Level Meta-analysis

Department of Psychology, University of Pennsylvania, 3720 Walnut St, Philadelphia, PA 19104, USA.
JAMA The Journal of the American Medical Association (Impact Factor: 30.39). 01/2010; 303(1):47-53. DOI: 10.1001/jama.2009.1943
Source: PubMed

ABSTRACT Antidepressant medications represent the best established treatment for major depressive disorder, but there is little evidence that they have a specific pharmacological effect relative to pill placebo for patients with less severe depression.
To estimate the relative benefit of medication vs placebo across a wide range of initial symptom severity in patients diagnosed with depression.
PubMed, PsycINFO, and the Cochrane Library databases were searched from January 1980 through March 2009, along with references from meta-analyses and reviews.
Randomized placebo-controlled trials of antidepressants approved by the Food and Drug Administration in the treatment of major or minor depressive disorder were selected. Studies were included if their authors provided the requisite original data, they comprised adult outpatients, they included a medication vs placebo comparison for at least 6 weeks, they did not exclude patients on the basis of a placebo washout period, and they used the Hamilton Depression Rating Scale (HDRS). Data from 6 studies (718 patients) were included.
Individual patient-level data were obtained from study authors.
Medication vs placebo differences varied substantially as a function of baseline severity. Among patients with HDRS scores below 23, Cohen d effect sizes for the difference between medication and placebo were estimated to be less than 0.20 (a standard definition of a small effect). Estimates of the magnitude of the superiority of medication over placebo increased with increases in baseline depression severity and crossed the threshold defined by the National Institute for Clinical Excellence for a clinically significant difference at a baseline HDRS score of 25.
The magnitude of benefit of antidepressant medication compared with placebo increases with severity of depression symptoms and may be minimal or nonexistent, on average, in patients with mild or moderate symptoms. For patients with very severe depression, the benefit of medications over placebo is substantial.


Available from: Richard C Shelton, Jan 31, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: The author grew up in Goa, a unique bicultural setting on the western coast of India. Goa came under Portuguese rule in 1510 AD and remained under the Portuguese until 1961 when it became part of India. The Indian and Portuguese cultures interacted in Goa and led the Goans to create an interesting blend in which elements of both cultures were made to reconcile. The author reviews his experiences in this setting and describes how his family background, his search for roots, and his exposure to two religions, two languages, and two cultures fostered his decision to study medicine, his passion for transcultural psychiatry, and eventual pursuit of an academic career in this field in the United States. Research and reflections are presented on the impact of colonization, migration, and acculturation, and the importance of the construct of demoralization.
    Transcultural Psychiatry 04/2011; 48(1-2):160-76. DOI:10.1177/1363461510388544 · 0.99 Impact Factor
  • 04/2015; DOI:10.1016/j.aimed.2015.02.001
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Meta-analyses indicate that antidepressants are superior to placebos in statistical terms, but the clinical relevance of the differences has not been established. Previous suggestions of clinically relevant effect sizes have not been supported by empirical evidence. In the current paper we apply an empirical method that consists of comparing scores obtained on the Hamilton rating scale for Depression (HAM-D) and scores from the Clinical Global Impressions - Improvement (CGI-I) scale. This method reveals that a HAM-D difference of 3 points is undetectable by clinicians using the CGI-I scale. A difference of 7 points on the HAM-D, or an effect size of 0.875, is required to correspond to a rating of 'minimal improvement' on the CGI-I. By these criteria differences between antidepressants and placebo in randomised controlled trials, including trials conducted with people diagnosed with very severe depression, are not detectable by clinicians and fall far short of levels consistent with clinically observable minimal levels of improvement. Clinical significance should be considered alongside statistical significance when making decisions about the approval and use of medications like antidepressants. Copyright © 2015. Published by Elsevier Inc.
    Contemporary clinical trials 05/2015; 43. DOI:10.1016/j.cct.2015.05.005 · 1.99 Impact Factor